1-6 of 6
Gregory P. Donoho
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma

Alyssa C. Flint, Dana K. Mitchell, Steven P. Angus, Abbi E. Smith, Waylan Bessler, Li Jiang, Henry Mang, Xiaohong Li, Qingbo Lu, Brooke Rodriguez, George E. Sandusky, Andi R. Masters, Chi Zhang, Pengtao Dang, Jenna Koenig, Gary L. Johnson, Weihua Shen, Jiangang Liu, Amit Aggarwal, Gregory P. Donoho, Melinda D. Willard, Shripad V. Bhagwat, D. Wade Clapp, Steven D. Rhodes
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (17): 3438–3456.
https://doi.org/10.1158/1078-0432.CCR-22-2854
Published: 01 September 2023
View article titled, Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma
Open the PDF for Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma in another window
Includes: Supplementary data
Journal Articles

Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer

Christopher J. Sweeney, Ivor J. Percent, Sunil Babu, Jennifer L. Cultrera, Bryan A. Mehlhaff, Oscar B. Goodman, David S. Morris, Ian D. Schnadig, Costantine Albany, Neal D. Shore, Paul R. Sieber, Susan C. Guba, Wei Zhang, Volker Wacheck, Gregory P. Donoho, Anna M. Szpurka, Sophie Callies, Boris Kin Lin, Johanna C. Bendell
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (11): 2237–2247.
https://doi.org/10.1158/1078-0432.CCR-21-2326
Published: 01 June 2022
View article titled, Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer
Open the PDF for Phase Ib/II Study of Enzalutamide with Samotolisib (LY3023414) or Placebo in Patients with Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor

David S. Hong, Kathleen N. Moore, Johanna C. Bendell, Daniel D. Karp, Judy S. Wang, Susanna V. Ulahannan, Suzanne Jones, Wenjuan Wu, Gregory P. Donoho, Yan Ding, Andrew Capen, Xuejing Wang, Aimee Bence Lin, Manish R. Patel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (7): 1864–1874.
https://doi.org/10.1158/1078-0432.CCR-20-3242
Published: 01 April 2021
View article titled, Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor
Open the PDF for Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor in another window
Includes: Supplementary data
Journal Articles

The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy

David A. Schaer, Sandaruwan Geeganage, Nelusha Amaladas, Zhao Hai Lu, Erik R. Rasmussen, Andreas Sonyi, Darin Chin, Andrew Capen, Yanxia Li, Catalina M. Meyer, Bonita D. Jones, Xiaodong Huang, Shuang Luo, Carmine Carpenito, Kenneth D. Roth, Alexander Nikolayev, Bo Tan, Manisha Brahmachary, Krishna Chodavarapu, Frank C. Dorsey, Jason R. Manro, Thompson N. Doman, Gregory P. Donoho, David Surguladze, Gerald E. Hall, Michael Kalos, Ruslan D. Novosiadly
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (23): 7175–7188.
https://doi.org/10.1158/1078-0432.CCR-19-0433
Published: 02 December 2019
View article titled, The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy
Open the PDF for The Folate Pathway Inhibitor Pemetrexed Pleiotropically Enhances Effects of Cancer Immunotherapy in another window
Includes: Supplementary data
Journal Articles

Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with BRAF or KRAS Mutations

Yung-mae M. Yao, Gregory P. Donoho, Philip W. Iversen, Youyan Zhang, Robert D. Van Horn, Amelie Forest, Ruslan D. Novosiadly, Yue Wang Webster, Philip Ebert, Steven Bray, Jason C. Ting, Amit Aggarwal, James R. Henry, Ramon V. Tiu, Gregory D. Plowman, Sheng-Bin Peng
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (18): 5547–5560.
https://doi.org/10.1158/1078-0432.CCR-16-3250
Published: 14 September 2017
View article titled, Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <em>BRAF</em> or <em>KRAS</em> Mutations
Open the PDF for Mouse PDX Trial Suggests Synergy of Concurrent Inhibition of RAF and EGFR in Colorectal Cancer with <em>BRAF</em> or <em>KRAS</em> Mutations in another window
Includes: Supplementary data
Journal Articles

Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

Wenjuan Wu, Chen Bi, Kelly M. Credille, Jason R. Manro, Victoria L. Peek, Gregory P. Donoho, Lei Yan, John A. Wijsman, S. Betty Yan, Richard A. Walgren
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2013) 19 (20): 5699–5710.
https://doi.org/10.1158/1078-0432.CCR-13-1758
Published: 14 October 2013
View article titled, Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Open the PDF for Inhibition of Tumor Growth and Metastasis in Non–Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET in another window
Includes: Supplementary data